BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1352 related articles for article (PubMed ID: 12599224)

  • 1. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
    Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
    Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
    Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
    Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
    Haq M; Harmer C
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results in elderly patients with differentiated thyroid carcinoma.
    Vini L; Hyer SL; Marshall J; A'Hern R; Harmer C
    Cancer; 2003 Jun; 97(11):2736-42. PubMed ID: 12767085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
    Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
    Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unilateral lobectomy for Hurthle cell adenoma.
    Wasvary H; Czako P; Poulik J; Lucas R
    Am Surg; 1998 Aug; 64(8):729-32; discussion 732-3. PubMed ID: 9697901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.
    Ghossein RA; Hiltzik DH; Carlson DL; Patel S; Shaha A; Shah JP; Tuttle RM; Singh B
    Cancer; 2006 Apr; 106(8):1669-76. PubMed ID: 16534796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery for thyroid Hürthle cell tumours--a single institution experience.
    Paunovic I; Krgovic K; Tatic S; Diklic A; Zivaljevic V; Kalezic N; Havelka M
    Eur J Surg Oncol; 2006 May; 32(4):458-61. PubMed ID: 16497473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma.
    Orita Y; Sugitani I; Matsuura M; Ushijima M; Tsukahara K; Fujimoto Y; Kawabata K
    Surgery; 2010 Mar; 147(3):424-31. PubMed ID: 20176243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality.
    Chow SM; Law SC; Chan JK; Au SK; Yau S; Lau WH
    Cancer; 2003 Jul; 98(1):31-40. PubMed ID: 12833452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial.
    Asari R; Koperek O; Scheuba C; Riss P; Kaserer K; Hoffmann M; Niederle B
    Ann Surg; 2009 Jun; 249(6):1023-31. PubMed ID: 19474675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart.
    Haigh PI; Urbach DR
    Surgery; 2005 Dec; 138(6):1152-7; discussion 1157-8. PubMed ID: 16360403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
    Vassilopoulou-Sellin R; Schultz PN; Haynie TP
    Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of previous radiation exposure on pathologic features and clinical outcome in patients with thyroid cancer.
    Seaberg RM; Eski S; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):355-9. PubMed ID: 19380356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of thyroid tumor aggressiveness.
    Clark OH
    West J Med; 1996 Sep; 165(3):131-8. PubMed ID: 8909165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hurthle cell tumor.
    Chen HY; Benjamin LB; Chen MF
    Int Surg; 1996; 81(2):168-70. PubMed ID: 8912085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hürthle cell tumors: a twenty-five-year experience.
    Arganini M; Behar R; Wu TC; Straus F; McCormick M; DeGroot LJ; Kaplan EL
    Surgery; 1986 Dec; 100(6):1108-15. PubMed ID: 3787466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma.
    Shoup M; Stojadinovic A; Nissan A; Ghossein RA; Freedman S; Brennan MF; Shah JP; Shaha AR
    J Am Coll Surg; 2003 Aug; 197(2):191-7. PubMed ID: 12892796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.